Biologic Therapeutic Drugs Technology Analysis and Global Market Forecast Report 2024-2025 & 2029 Featuring Key Players - Merck, F. Hoffmann-La Roche, Johnson & Johnson, Pfizer, & Bristol-Myers Squibb
DUBLIN--(BUSINESS WIRE)--Jun 11, 2025--
The 'Biologic Therapeutic Drugs: Technologies and Global Markets' report has been added to ResearchAndMarkets.com's offering.
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029.
The pharmaceutical industry is undergoing tremendous transformations by focusing more on targeted and personalized therapies. The industry is witnessing a shift from traditional synthetic drugs to biologic therapeutic drugs, which are more efficacious, have better patient outcomes and improve quality of life. Biologic drugs are primarily classified into monoclonal antibodies; vaccines; peptide hormones; cell and gene therapies; and others, which include protein therapeutics (e.g., cytokines, enzymes, blood factors, fusion proteins) and other drugs (e.g., RNA-based therapies).
The biopharmaceutical industry has recently been witnessing tremendous growth due to the increasing demand for innovative therapies, such as monoclonal antibodies, cell and gene therapies and vaccines. The demand for these therapies is primarily driven by such factors as the increasing prevalence of chronic diseases, rising healthcare expenditures, increasing awareness, novel product launches and strong pipelines. The biologic approvals by the U.S. Food and Drug Administration (FDA) are increasing year on year, and 2023 was marked by the approval of two breakthrough therapies: the gene editing therapy Casgevy from Vertex Pharmaceutical and Leqembi (lecanemab) from Eisai Inc.
The entry of biosimilars into the market is expected to erode the revenues of the current branded products upon patent expiry. The complex manufacturing process, a lack of skilled workforce and high development costs translate to a high cost of therapy, which acts as a major barrier to the market.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.
The report includes:
Company Profiles
Key Attributes:
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective
Chapter 9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/lsetb6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250611945349/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH TECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 06/11/2025 08:33 AM/DISC: 06/11/2025 08:32 AM
http://www.businesswire.com/news/home/20250611945349/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
30 minutes ago
- CNET
Google Has a New AI-Weather Model for Cyclones. Should Experts Trust It?
On Thursday, Google announced an advancement powered by artificial intelligence that could change the way we predict hurricanes. Weather Lab is an interactive website that shows live and historic AI weather models, including its latest tropical cyclone model, which includes hurricanes. It was developed by Google DeepMind, the company's London-based AI research lab. The cyclone model can predict the formation, track, intensity, size and shape of the storm. And it can create 50 possible scenarios up to 15 days ahead. A representative for Google did not immediately respond to a request for comment. How to use Weather Lab Weather Lab's website lets experts compare AI weather models to physics-based models from the European Centre for Medium-Range Weather Forecasts to get more cyclone information sooner. If experts are able to predict the storm earlier than a physics model, the extra time could help you and experts prepare for the impact of storms, especially those that could be life-threatening. The problem with physics-based models is that they don't track a cyclone's intensity or track as accurately as Google's AI-powered model. When experts look at both types of models, "they can better anticipate a cyclone's path and intensity," according to Google. The lab is running a few AI weather models in real time, but has included two years of previous predictions on the website so other researchers and experts can evaluate the models Google Deep Mind is creating. The two years researched used are not specified. Don't ditch other weather services It's worth noting that the Weather Lab can be helpful for future hurricane seasons and maybe even this one. Weather Lab accurately predicted the paths of two 2025 cyclones, Honde and Garance. Other storm paths were accurately predicted almost seven days in advance. Google DeepMind partnered with the US National Hurricane Center to confirm that their approach and outputs were correct to make predictions. However, Weather Lab is a research tool and even the live predictions are not official warnings. The lab still recommends relying on your local or national weather service.
New York Times
an hour ago
- New York Times
Blackburn Rovers set to make at least 20 women's team staff members redundant
Blackburn Rovers Women staff will take part in a redundancy process that could impact at least 20 members of staff, while all senior players are set to be released at the end of June, according to people familiar with the process. The club announced in May that their senior women's team were to be demoted from Women's Super League 2 — they had finished 10th in English football's second tier, five points clear of relegation. The club's ownership, the V H Group, which took over in November 2010, decided against meeting the required licensing criteria to retain their second tier status. Advertisement On Thursday, senior women's staff members received an email informing them that a 'group consultation process' was set to begin regarding their employment with the club, according to sources who wished to remain anonymous to protect relationships. The proposed redundancies impact all staff within the women's football department, including pathway and operations staff and medical staff, as well as marketing and communications personnel. The number of redundancies is said to surpass 20, which would remove most of the contracted staff working within the club's women's football department. The email informing staff of the impending redundancy process was said to be the first form of communication from the club hierarchy since Blackburn's decision to demote the women's senior team. Many members of staff say they have resigned themselves to searching for jobs elsewhere. A source with knowledge of the situation indicated internal discussions with relevant club staff remain ongoing, and staff have been informed they will continue to be paid until the consultation process has been finalised. Players are also set to be released at the end of the month following the expiration of their contracts, according to those close to the decision. A number of players saw options in their contracts triggered last summer, thereby keeping them at average salaries of £9,000 ($12,152), despite an increase in training sessions from three evenings a week to four days. Players had previously been informed that the club was not in a position to offer them a contract beyond the 2024-25 season, and they have been told they will be paid up until the end of their contracts. What the structure of the women's team would look like following redundancies and player departures is very uncertain. Regulations for the women's pyramid state that any club that withdraws from a league can only re‑enter at least two tiers lower, where teams largely operate on a volunteer basis with no elite pathways. Advertisement Blackburn confirmed at the start of June they will play in the National League Division 1 North next season, the fourth tier of the women's football pyramid. According to FA NWL rules, each team must have at least 11 players registered 14 days before the start of the season. The 2025-26 season commences on September 6. A failure to do so will result in a £50 fine. According to people familiar with the decision, the ownership did not wish to commit more than £100,000 into their women's team's playing budget for the 2025-26 season, which would not meet the minimum threshold introduced by WSL Football. Blackburn did not comment on the figure to The Athletic when asked in May other than to say they spent around £500,000 on the women's team for the 2024-25 season.
Bloomberg
4 hours ago
- Bloomberg
Qualitas Leads Bidding for $8 Billion Clean Energy Firm Cubico
Spain's largest renewable fund Qualitas Energy is the frontrunner to acquire clean-energy company Cubico Sustainable Investments, according to people with knowledge of the matter. Qualitas has emerged as the leading bidder for the business after interest from KKR & Co. 's ContourGlobal, the other remaining suitor, has cooled, the people said, asking not to be identified as the information is private.
